Organization | James R. Berenson MD, Inc.

James R. Berenson MD, Inc. Report issue

Academic/Hospital Phase 2 Phase 3

Founded: West Hollywood CA United States (1998)

Organization Overview

First Clinical Trial

2009

NCT01160484

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2014

Timeline

NOW

Now

Alternative names

James R. Berenson, M.D., Inc. | James R. Berenson, MD, Inc. | James R. Berenson, MD., Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

armodafinil (nuvigil) (1 trial)

Drugs in Phase 2 Trials (12)

bortezomib (velcade) (4 trials)

carfilzomib (kyprolis) (3 trials)

clarithromycin (biaxin) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

doxorubicin (Doxil) (3 trials)

lenalidomide (revlimid) (2 trials)

melphalan (alkeran) (1 trial)

methylprednisolone (medrol) (2 trials)

pomalidomide (pomalyst) (1 trial)

prednisone (meticorten) (2 trials)

urea (3 trials)

vitamin c (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Fatigue (Phase 3)

Multiple Myeloma (Phase 3)

Neoplasms, Plasma Cell (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 7
# of Trial APIs: 13